Brainstorm Cell buy BiotechBee
Summary
This prediction ended on 10.12.23 with a price of €0.18. The prediction for Brainstorm Cell disappointed with a performance of -29.60%. BiotechBee has 50% into this predictionBrainstorm Cell Therapeutics Inc. (Symbol: BCLI) is a biotechnology company specializing in the development of innovative adult stem cell therapies for central nervous system (CNS) diseases and disorders. Headquartered in New York, the company is dedicated to leveraging its proprietary NurOwn platform, which uses autologous, patient-derived cells to treat neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). By enhancing the cells' ability to secrete neurotrophic factors (NTFs) that support nerve cells' growth, survival, and function, Brainstorm Cell is at the forefront of clinical research to address the unmet need for therapies in this rapidly evolving field. As a publicly traded company, BCLI is listed on the Nasdaq stock exchange, offering prospective investors a unique opportunity to invest in a pioneering biotech company aiming to transform the lives of millions living with neurodegenerative diseases.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Brainstorm Cell | -12.877% | -12.877% |
| iShares Core DAX® | -0.116% | 1.953% |
| iShares Nasdaq 100 | -2.733% | -1.273% |
| iShares Nikkei 225® | -1.721% | 3.263% |
| iShares S&P 500 | -1.527% | 0.194% |